Related Experiment Video

Updated: Aug 17, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

VAV1: a new target in pancreatic cancer?

Gina Denicola1, David A Tuveson

  • 1Department of Cancer Biology, Abramson Family Cancer Research Institute, The Abramson Cancer Center at the University of Pennsylvania Medical Center, Philadelphia, PA, USA.

Cancer Biology & Therapy
|June 23, 2005
PubMed

Insights

Pancreatic cancer (PDA) cells show abnormal VAV1 expression due to gene demethylation. This VAV1 protein is crucial for cancer cell growth and survival, offering new therapeutic targets for pancreatic cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with limited effective treatments.
  • Molecular alterations identified in PDA have not yet yielded successful therapeutic strategies.
  • The role of specific genes in pancreatic tumorigenesis remains an active area of research.

Purpose of the Study:

  • To investigate the role of the hematopoietic-specific RhoGEF VAV1 in pancreatic tumorigenesis.
  • To determine if VAV1 expression is altered in pancreatic cancer and if it impacts cancer cell behavior.
  • To explore VAV1 as a potential therapeutic target for PDA.

Main Methods:

  • Analysis of VAV1 expression in pancreatic cancer cell lines and tissue samples.
  • Investigation of VAV1 promoter methylation status.
  • Functional assays to assess the impact of VAV1 on cancer cell proliferation, transformation, and survival.

Main Results:

  • Ectopic expression of VAV1 was found in the majority of established PDA cell lines and tumor samples.
  • VAV1 expression was linked to VAV1 promoter demethylation, an event in cancer progression.
  • VAV1 expression was essential for the proliferation, transformation, and survival of pancreatic cancer cell lines.

Conclusions:

  • Aberrant VAV1 signaling, driven by promoter demethylation, plays a significant role in pancreatic cancer progression.
  • VAV1 represents a novel and promising therapeutic target for pancreatic ductal adenocarcinoma.
  • Further research into VAV1-driven pathways could lead to improved treatment strategies for PDA.

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Acute Pancreatitis I: Introduction01:25

Acute Pancreatitis I: Introduction

Acute pancreatitis is the sudden inflammation of the pancreas caused by the early activation of digestive enzymes, leading to the autodigestion of pancreatic tissue. This results in local inflammation and, in severe cases, systemic complications.EtiologyUnderstanding the underlying causes is crucial, as identifying the etiology guides treatment and anticipates complications. Acute pancreatitis can be triggered by various factors, typically grouped into the following clinical categories.Biliary...